Compare Gold Fields Limited (GFI) vs Repligen Corporation Common Stock (RGEN) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Gold Fields Limited vs Repligen Corporation Common Stock — how do they compare? Gold Fields Limited trades at $36.68 (market cap $32.51B), while Repligen Corporation Common Stock trades at $178.15 (market cap $11.14B). The key difference: Gold Fields Limited is far larger — about 2.9× Repligen Corporation Common Stock's market cap, and Gold Fields Limited pays a 5.92% dividend while Repligen Corporation Common Stock pays none. Which is the better fit depends on your goals — on Pluang, investors hold Gold Fields Limited for 50 Days and Repligen Corporation Common Stock for 0 Days on average.
| GFI | RGEN | |
|---|---|---|
Market Cap | $32.51B | $11.14B |
Volume | 3,490,155 | 1,259,263 |
Sector | Basic Materials | Health |
52-Week High | $61.52 | $194.57 |
52-Week Low | $31.25 | $102.87 |
Typical Hold Time | 50 Days | 0 Days |
Enterprise Value | $33.11B | $11.02B |
Dividend Yield | 5.92% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Gold Fields (GFI) trades at $35.55, down 3.29% amid market reaction to its rejected $27 billion bid for Northern Star. Despite recent earnings misses, the company shows strong fundamentals with a low P/E of 7.4, robust net income margin of 38.66%, and record 2025 revenue of $8.75 billion. Technical indicators are bearish, with the stock near key support at $36. Analyst consensus remains positive with a $52.75 price target, though sentiment is cautious due to acquisition uncertainty.
The outlook for GFI is mixed; its undervalued metrics and high profitability support upside potential, but near-term volatility from the failed acquisition and bearish technicals pose risks. Investors should weigh the company's strong cash flow generation and growth prospects against execution risks and gold price sensitivity.
RGEN trades at $175.42, up 1.66% today, with a neutral technical signal and key support at $173. The stock has consistently beaten earnings estimates in recent quarters, with Q3 2026 results due October 27. Revenue grew to $738.26M in 2025, though net income margin is modest at 5.29%. The company recently completed the acquisition of BioLife Solutions, signaling strategic expansion.
Outlook remains positive with strong analyst support (91.67% buy ratings) and a consensus price target of $173.86, though high valuation multiples (P/E 240.34) pose a risk. Earnings growth and integration of acquisitions are key catalysts, but investors face execution risks and market volatility.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Gold Fields Limited
Gold Fields Ltd is a producer of gold and is a holder of gold reserves and resources in South Africa, Ghana, Australia and Peru. In Peru, the company also produces copper. The company is primarily involved in underground and surface gold and surface copper mining and silver and related activities, including exploration, extraction, processing and smelting. It conducts underground and surface mining operations at St. Ives, underground-only operations at Agnew, Granny Smith and South Deep and surface-only open pit mining at Damang, Tarkwa and Cerro Corona. The company's revenues are derived from the sale of gold that it produces.
Read more on GFI →About Repligen Corporation Common Stock
Repligen Corporation develops and manufactures bioprocessing tools and technologies used in biologic drug manufacturing, including filtration and perfusion systems, chromatography columns and resins, and process analytics instruments. Its products support upstream and downstream production workflows for modalities such as monoclonal antibodies, mRNA, and viral vectors.
Read more on RGEN →
